A new statistical method for dose-finding based on efficacy and toxicity in early phase clinical trials

Investigational New Drugs

Volumn 17, Issue 2, 1999, Pages 155-167

  Thall, Peter F ^a   Estey, Elihu H ^a   Sung, Hsi Guang ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Bayesian inference; Clinical trial; Dose finding study; Phase I trial; Phase II trial; Safety monitoring

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; FLUDARABINE; INTERLEUKIN 12;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOXICITY; HUMAN; LEUKAPHERESIS; MATHEMATICAL MODEL; MAXIMUM PERMISSIBLE DOSE; MYELODYSPLASTIC SYNDROME; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROBABILITY; SALVAGE THERAPY; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 0032794987     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006323317135     Document Type: Article

References (19)

1. Thall PF, Russell KE: A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics 54: 251-264, 1998
2. Thall PF: Safer Bayesian dose-finding based on efficacy and toxicity in early phase clinical trials. Unpublished manuscript
3. Storer BE: Design and analysis of phase I clinical trials. Biometrics 45: 925-937, 1989
4. O'Quigley J, Pepe M, Fisher L: Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 46: 33-48, 1990
5. O'Quigley J, Shen LZ: Continual reassessment method: a likelihood approach. Biometrics 52: 673-684, 1996
6. Korn EL, Midthune D, Chen TT, Rubinstein LV, Christian MC, Simon RM: A comparison of two phase I trial designs. Statistics in Medicine 13: 1799-1806, 1994
7. Møller S: An extension of the continual reassessment methods using a preliminary up-and-down design in a dose-finding study in cancer patients, in order to investigate a greater range of doses. Statistics in Medicine 14: 911-922, 1995
8. Goodman SN, Zahurak ML, Piantadosi S: Some practical improvements in the continual reassessment method for phase I studies. Statistics in Medicine 14: 1149-1161, 1995
9. Thall PF, Lee JJ, Tseng C-H, Estey EH: Accrual strategies for phase I trials with delayed patient outcome. Statistics in Medicine 18: 1155-1169, 1999
10. Freireich EJ, Gehan EA, Sulman D, Boggs DR, Frei E III: The effect of chemotherapy on acute leukemia in the human. J Chronic Disease 14: 593-608, 1961
11. Shen Y, Thall PF: Parametric likelihoods for multiple nonfatal competing risks and death. Statistics in Medicine 17: 999-1016, 1998
12. Estey EH, Shen Y, Thall PF: Effect of time to achieve CR on subsequent survival time in patients with newly-diagnosed AML, RAEB-t, or RAEB in whom response is established after the first course of chemotherapy. Blood, In press
13. Thall PF, Simon R: Recent developments in the design of phase II clinical trials. In: Thall PF (ed) Recent Advances in Clinical Trial Design and Analysis. Kluwer, Boston, 1995 pp 49-71
14. Thall PF, Simon R, Estey EH: Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Statistics in Medicine 14: 357-379, 1995
15. Press J: Bayesian Statistics: Principles, Models, and Applications. Wiley, New York, 1989
16. Berry DA: Monitoring accumulating data in a clinical trial. Biometrics 45: 1197-1211, 1989
17. Berry DA: A case for Bayesianism in clinical trials (with discussion). Statistics in Medicine 12: 1377-1404, 1993
18. Gelman A, Carlin JB, Stern H, Rubin DB: Bayesian Data Analysis. Chapman and Hall, London, 1995
19. Berry DA, Stangl DK (eds): Bayesian Biostatistics. Dekker, New York, 1996